Amplion, a startup that helps healthcare companies sort through biological data, closed a Series A fundraising round led by Greycroft with participation from existing investors Revolution’s Rise of the Rest Seed Fund and Imagen Capital Partners. The Bend, Ore.-based company plans to put the fresh cash into sales, marketing and product development efforts. It declined to say how much was raised as part of the round.
Amanda Enstrom, chief product officer at Amplion. (Amplion Photo)
“Every week there are thousands of clinical trials as well as research articles being published,” said Dr. Amanda Enstrom, chief product officer at Amplion. “Precision medicine really needs to be able to quickly synthesize a subset of information. It’s critical to their drug development process.”
Amplion’s core product, called Biomarkerbase, combs through information published to resources such as ClinicalTrials.org or PubMed.gov and identifies therapeutically important biomarkers, which are molecules that indicate diseases and other biological states. Those biomarkers are then used by healthcare organizations for research, diagnostics and drug development. Amplion’s clients include Shire, Thermo Fisher Scientific and Bio-Rad Laboratories.
“The body of work surrounding biomarkers has gone far beyond human scale in terms of both breadth and fluidity,” Will Szczerbiak, principal at Greycroft, said …read more